Measuring of Neuro-visual Functionality With Ocusweep
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02258113|
Recruitment Status : Recruiting
First Posted : October 7, 2014
Last Update Posted : October 17, 2017
|Condition or disease||Intervention/treatment||Phase|
|Visual Impairment||Device: Ocusweep||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||600 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Measuring of Neuro-visual Functionality With New Human Visual System Device Ocusweep|
|Study Start Date :||November 2014|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 31, 2017|
LEA numbers, Pelli-Robson, Octopus
Comparable generally used method for measuring visual acuity, contrast sensitivity and visual field.
A novel reaction-time based visual field device.
- Visual acuity [ Time Frame: One visit per one patient (1h/visit) ]Visual acuity is measured as logMAR unit at the one visit for each patient using a novel reaction-time based visual field device and comparable method.
- Contrast sensitivity [ Time Frame: One visit per one patient (1h/visit) ]Contrast sensitivity is measured as logCS unit at the one visit for each patient using a novel reaction-time based visual field device and comparable method.
- Reaction time [ Time Frame: One visit per one patient (1h/visit) ]Reaction time is measured using a novel reaction-time based visual field device and compared with generally used visual field program.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02258113
|Contact: Marika Ojala, Mrsemail@example.com|
|Contact: Markku Leinonen, Drfirstname.lastname@example.org|
|Turku, Finland, 20100|
|Contact: Marika Ojala, MSc email@example.com|
|Contact: Markku Leinonen, Dr firstname.lastname@example.org|